Optimind Pharma Corp.
OMND
CNSX
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -35.67% | 154.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.67% | 154.24% | |||
| Cost of Revenue | -20.20% | 12.50% | |||
| Gross Profit | -43.28% | 570.00% | |||
| SG&A Expenses | -78.67% | 5.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -72.12% | 6.24% | |||
| Operating Income | 91.37% | 18.74% | |||
| Income Before Tax | 89.05% | 15.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 89.05% | 15.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.05% | 15.66% | |||
| EBIT | 91.37% | 18.74% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 83.33% | 0.00% | |||
| Normalized Basic EPS | 100.00% | 25.00% | |||
| EPS Diluted | 83.33% | 0.00% | |||
| Normalized Diluted EPS | 100.00% | 25.00% | |||
| Average Basic Shares Outstanding | 0.52% | -6.56% | |||
| Average Diluted Shares Outstanding | 0.52% | -6.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
